Movement disorders
Conditions
Interventions
Low frequency rTMS treatment group:Low frequency (1Hz) rTMS
Shame stimulation control group:Shame stimulation
Sponsors
Xuanwu Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Age range from 65 to 80 years old, gender unlimited; 2.Symptoms of motor disorders: Tinetti Balance and Gait Assessment (POMA) <=24 points; 3.The STRIVE-2 diagnostic criteria for cSVD include white matter hyperintensities (WMH), perivascular spaces (PVS), recent small subcortical infarcts (RSSI), lacunae, cerebral microbleeds (CMB), cortical surface iron deposition, convex subarachnoid hemorrhage (cSAH), spontaneous cerebral hemorrhage, cerebral atrophy, cortical microbleeds, and occasional DWI positive lesions; 4.The condition is stable and it is expected that there will be no significant medication adjustments during the treatment period. Long term follow-up is agreed; 5.Patients and their families understand all study content and sign informed consent
Exclusion criteria
Exclusion criteria: 1.Clinically significant motor disorders, including diagnosable PD, dystonia, HD, tic disorders, and idiopathic tremors; 2.Received physical stimulation therapy such as TMS within one year prior to enrollment; 3.Unable to understand the article, cooperate with the examination, or any other factors that may hinder the completion of the neurokinematic evaluation; 4.Cardiovascular and cerebrovascular diseases, lung diseases, liver diseases, kidney diseases, autoimmune or inflammatory diseases, metabolic and endocrine disorders with clinical significance, as well as serious neurological and psychiatric diseases such as AD, FTD, LBD, PD, schizophrenia, severe depression, epilepsy, etc; 5.Any tumor disease (including erythrocytosis, excluding basal cell carcinoma or squamous cell carcinoma); 6.History of alcohol or drug abuse; 7.Sudden changes in bodily functions such as falls, fainting, or delirium within 30 days; 8.Expected life<6 months; 9.Known contraindications for TMS (epilepsy, antidepressants, antipsychotic drugs, benzodiazepines, antibiotics, and implanted electrical/metal devices in the head); 10.Participate in other studies within one month prior to baseline; 11.Refusal to sign informed consent form, poor compliance, or inability to cooperate in completing complete treatment; 12.The researchers believe that there are situations where it is not appropriate to participate in this study;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in motor evaluation parameters; | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse event;Changes in imaging; | — |
Countries
China
Contacts
Public ContactHaiqing Song
Xuanwu Hospital Capital Medical University
Outcome results
None listed